Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure
Ask the expert
The report presents a summary of reimbursement situation for Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure.
Both veno-venous and veno-arterial ECMO is considered.
The use of ECMO is considered in the following situations:
- Acute respiratory distress syndrome (VV-ECMO)
- Deterioration of chronic advanced heart failure (VA-ECMO)
- Post-cardiotomy cardiogenic shock (VA-ECMO)
- Post-myocardial infarction cardiogenic shock (VA-ECMO)
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
Manufacturers of extra-corporeal membrane oxygenation devices for pulmonary and cardiac failure report include:
- Abbott Vascular (CentriMag, PediVAS)
- Fresenius / XENIOS AG (Medos device)
- Getinge (CARDIOHELP System, Rotaflow Centrifugal Pump System, PLS System)
- Hemovent GmbH (Portable ECMO system)
- Medtronic (BPX-80, BP-50)
- Terumo (CAPIOX SP Centrifugal Pump)
Table of content is not available at the moment.